Head-to-head evidence
ADR-002K vs Anhui HygeianCells EE001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline
ADR-002K
Developed by Rohto Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Anhui HygeianCells EE001
Developed by Anhui HygeianCells BioMedical
NCT06884111 · Phase 1 · completed
Only 6 people received the drug, all in a single open, unblinded group with no placebo or comparison arm, so any change seen cannot be attributed to the drug with confidence. No results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ADR-002K's landscape · Anhui HygeianCells EE001's landscape